Unresolved inflammation: 'Immune tsunami' or erosion of integrity in immune-privileged and immune-responsive tissues and acute and chronic inflammatory diseases or cancer

Expert Opinion on Biological Therapy

Volumn 11, Issue 11, 2011, Pages 1419-1432

  Khatami, Mahin ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acute and chronic inflammation; Angiogenesis; Autoimmune; BBB; Cancer; CNS; Cornea; Dendritic cells; Hyperplasia; Immune surveillance; Immune tolerance; Immune privilege; Innate and adaptive immune cells; Macrophages; Mast cells; Natural killer cells; Neovascularization; Neurodegenerative; Neuroretina; Tissue integrity

Indexed keywords

CCL1 CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CYCLOOXYGENASE 1; CYTOKINE; EOSINOPHIL PROTEIN X; EOTAXIN; HEPARIN; HISTAMINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 2; LIPOXYGENASE; MEMBRANE ENZYME; MONOCYTE CHEMOTACTIC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN LYSINE 6 OXIDASE; RANTES; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNINDEXED DRUG;

AGE; ANGIOGENESIS; APOPTOSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CACHEXIA; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM; CHRONIC INFLAMMATION; DEGENERATIVE DISEASE; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE PREDISPOSITION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNE TSUNAMI; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSURVEILLANCE; INFLAMMATORY DISEASE; INNATE IMMUNITY; MACROPHAGE; METASTASIS; MULTIPLE ORGAN FAILURE; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; TUMOR GROWTH; VASCULARIZATION; WOUND HEALING;

ACUTE DISEASE; ADAPTIVE IMMUNITY; AGING; ANIMALS; APOPTOSIS; CHRONIC DISEASE; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; NEOPLASMS; WOUND HEALING;

EID: 80053643341     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.592826     Document Type: Review

References (76)

1. Khatami M. 'Yin' and 'Yang' in inflammation: duality in innate immune cell function and Tumorigenesis. Exp Opin Biol Ther 2008;8:1461-72
2. Khatami M. Inflammation, aging and cancer: tumoricidal vs tumorigenesis of immunity: a common denominator in chronic diseases. Cell Biochem Biophys 2009;55:55-79
3. Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T cell inhibition and application to cancer therapy. Immunol Rev 2008;224:141-65
4. Soehnlein O, Lindbom L. Phagocyte partnership during the onset and resolution of inflammation. Nature Rev Immunol 2010;10:427-39
5. Berosbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 2009;7:99-109
6. Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008;111:5271-81
7. Harrois A, Huet O, Duranteau J. Alterations of mitochondrial function in sepsis and critical illness. Curr Opin Anaesthesiol 2009;22:143-9
8. Deitch EA. Gut lumph and lymphatics: a source of factors leading to organ injury and dysfunction. Ann NY Acad Sci 2010;1207(Suppl 1):E103-11
9. London NR, Zhu W, Bozza FA, et al. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med 2010;17:23
10. Akdis M. T cell tolerance to inhaled allergens: mechanisms and therapeutic approaches. Expert Opin Biol Ther 2008;8:769-77 (Pubitemid 351860206)
11. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004;22:307-28 (Pubitemid 38680425)
12. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2005;5:953-64
13. Kabelitz D, Medzhitov R. Innate immunity-cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr Opin Immunol 2006;19:1-3
14. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25:677-86 (Pubitemid 39457982)
15. Khatami M. Developmental phases of inflammation-induced massive lymphoid hyperplasia and extensive changes in epithelium in an experimental model of allergy. Implications for a direct link between inflammation and carcinogenesis. Am J Ther 2005;12:117-28
16. Khatami M. Cyclooxygenase inhibitor Ketorolac or mast cell stabilizers: Immunological challenges in cancer therapy. Clin Cancer Res 2005;11:1350-2
17. Erwig LP, Henson PM. Immunological consequences of apoptic cell phagocytosis. Am J Pathol 2007;171:2-8 (Pubitemid 47339220)
18. De Lorenzo BHP, Godoy LC, Novaese Brito RR, et al. Macrophage suppression following phagocytosis of apoptotic neutrophils is mediated by S100A9 calcium-binding protein. Immunobiology 2010;215:340-7
19. Khatami M, Donnelly JJ, John T, Rockey JH. Vernal conjunctivitis. Model studies in guinea pigs immunized topically with fluoresceinyl ovalbumin. Arch Ophthalmol 1984;102:1683-8
20. Khatami M, Donnelly JJ, Haldar JP, Rockey JH. Massive follicular lymphoid hyperplasia in experimental chronic recurrent allergic conjunctivitis. Arch Ophthalmol 1989;107:433-8 (Pubitemid 19078292)
21. Khatami M, Donnelly JJ, Rockey JH. Induction and down-regulation of conjunctival type-1 hypersensitivity reactions in guinea pigs sensitized topically with fluoresceinyl ovalbumin. Ophthalmic Res 1985;17:139-47 (Pubitemid 15116163)
22. Haldar JP, Khatami M, Lok JB, et al. Experimental ocular oncocerchiasis. Local and systemic antibody and cell mediated immune response. Trop Med Parasitol 1990;41:234-40 (Pubitemid 20332748)
23. Helleboid L, Khatami M, Wei Z-G, Rockey JH. Histamine and prostacyclin: Primary and secondary release in allergic conjunctivitis. Invest Ophthalmol Vis Sci 1991;32:2281-9
24. Suzuki M, Kobayashi H, Ohwada M, et al. Macrophage-colony stimulating factor as a marker for malignant germ cell tumors of the ovary. Gynecol Oncol 1998;68:35-7 (Pubitemid 28109820)
25. Ibrahim R, Frederickson H, Parr A, et al. Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism. Cancer 2006;106:1065-77
26. Sethi G, Sung B, Aggarwal BB. TNF: A master switch for inflammation and cancer. Front Biosci 2008;13:5094-107 (Pubitemid 351599660)
27. Muller AJ, Sharma MD, Chandler PR, et al. Chronic inflammation that facilitate tumor progression create local immune suppression by inducing indoleamine 2, 3 dioxygenase. Proc Natl Acad Sci 2008;105:17073-8
28. Nardin A, Abastado JP. Macrophages and cancer. Front Biosci 2008;13:3494-505 (Pubitemid 351594699)
29. Khatami M. Standardizing cancer biomarkers criteria: data elements as a foundation for a database. Inflammatory mediator/M-CSF as model marker. Cell Biochem Biophysics 2007;47:187-98 (Pubitemid 47338361)
30. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med 2007;7:777-89
31. Ning Y, Wang L, Giovannucci EL. Obesity comorbidities: a quantitative analysis of body mass index and colorectal cancer: finding from 56 observational studies. Obesity Rev 2010;11:19-30
32. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancer of the colon, prostate, and pancreas. Gastroenterology 2007;132:2208-25 (Pubitemid 46693749)
33. Hotamisisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-7
34. Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nature Immunol 2006;7:354-9
35. Lee HO, Herndon JM, Barreiro R, Ferguson TA. TRAIL: a mechanism of tumor surveillance in an immune privileged site. J Immunol 2002;169:4739-47
36. Wada H, Masuda K, Satoh R, et al. Adult T-cell progenitors retain myeloid potential. Nature 2008;10452:768-72 (Pubitemid 351521082)
37. Zamiri P, Sugita S, Streilein JW. Immunosuppressive properties of the pigmented epithelial cells and the subretinal space. Chem Immunol Allerg 2007;92:86-93 (Pubitemid 47096898)
38. Naito M, Itoh M. Patterns of infiltration of lymphocytes into the testis under normal and pathological conditions in mice. Am J Reprod Immunol 2008;59:55-61 (Pubitemid 350285583)
39. Siffrin V, Brandt AU, Herz J, Zipp F. New insights into adaptive immunity in chronic neuroinflammation. Adv Immunol 2007;96:1-40 (Pubitemid 350027721)
40. Booman M, Suzuhai K, Rosenwald A, et al. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged site: the importance of apoptosis and immunomodulatory pathways. J Pathol 2008;216:209-17
41. Merad M, Romani N, Randolph G. Langerhans cells at the interface of medicine, Science, and industry. J Invest Dermatol 2008;128:251-5
42. Clausen BE, Kel JM. Langerhans cells: critical regulators of skin immunity? Immunol cell Biol 2010;88:351-60
43. Bonetti B, Valdo P, Ossi G, et al. T-cell cytotoxicity of human Schwann cell: TNF-alpha promotes fasL-mediated apoptosis and IFNgamma perforin-mediated lysis. Glia 2003;43:141-8 (Pubitemid 36897275)
44. Fischer HG, Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol 2001;166:2717-26 (Pubitemid 32173513)
45. Hamrah P, Huq SO, Liu Y, et al. Corneal immunity is mediated by heterogeneous population of antigen-presenting cells. J Leukoc Biol 2003;74:172-8 (Pubitemid 38040413)
46. O'Connell J. Immune privilege or inflammation? The paradoxical effects of fas ligand Arch Immunol Ther Exp (Warsz) 2000;48:73-9
47. Ferguson TA, Griffith TS. The role of fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response. Chem Immunol Allergy 2007;92:140-54 (Pubitemid 47096903)
48. Kwidzinski E, Mutlu LK, Kovac AD, et al. Self-tolerance in the immune privileged CNS: lessons from the entorhinal cortex lesion model. J Neural Transm Suppl 2003;65:29-49 (Pubitemid 38344138)
49. Knoernschild T, Grasbon T, Wilsch C, et al. RPE cell transplants to non-immune-privileged sites of the eye transform into fibroblast-like cells. Curr Eye Res 2003;27:25-34 (Pubitemid 36936344)
50. Sugita S. Role of ocular pigment epithelial cells in immune privilege. Arch Immunol Ther Exp (Warsz) 2009;57:263-2688
51. Widera D, Kaus A, Kaltschmidt C, Kaltschmidt B. Neuronal stem cell, inflammation and NF-kB: basic principle of maintenance and repair or origin of brain tumours? Neuroscience Rev Series 2008;12:459-70 (Pubitemid 351555127)
52. Ponomarev ED, Shriver LP, Maresz K, et al. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the autoimmune encephalomyelitis. J Immunol 2007;178:39-48 (Pubitemid 46039660)
53. Barcia RN, Dana MR, Kazlauskas A. Corneal graft rejection is accompanied by apoptosis of the endothelium and is prevented by gene therapy with bcl-xL. Am J Transplantation 2007;7:2082-9 (Pubitemid 47247044)
54. Karman J, Ling C, Sauder M, Fabry Z. Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol 2004;173:2353-61 (Pubitemid 39063091)
55. Dheen ST, Kaur C, Ling EA. Microglial activation and its implications in the brain diseases. Curr Med Chem 2007;14:1189-97 (Pubitemid 46739320)
56. Ren JL, Pan JS, Lu YP, et al. Inflammatory signaling and cellular senescence. Cell Signal 2009;21:378-83
57. Ginaldi L, Martinis MD, Monti D, Franceschi C. Chronic antigenic load and apoptosis in immunoscenescence. Trends in Immunol 2005;28:79-84
58. Campisi J. Cellular senescence; putting the paradox in perspective. Curr Opin Genet Dev 2011;21:107-12
59. Davalos AR, Coppe JP, Campisi J, Desprez PY. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev 2010;29:273-83
60. Ignarro LJ, Napoli C. Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis. Curr Diab Rep 2005;5:17-23 (Pubitemid 40277796)
61. De La Fuente M, Hernandez A, Vallejo MC. The immune system in the oxidative stress conditions of aging and hypertension: favorable effects of antioxidants and physical exercise. Antioxid Redox Signal 2005;7:1356-66 (Pubitemid 41232533)
62. Goronzy JJ, Weyand CM. T cell development and receptor diversity during aging. Curr Opin Immunol 2005;17:468-75 (Pubitemid 41207948)
63. Sansoni P, Vescovoni R, Fagnoni F, et al. The immune system in extreme longevity. Exp Gerontol 2008;43:61-5
64. Nagai M, Hoshide S, Kairo K. Hypertension and dementia. Am J Hypertension 2010;23:116-24
65. Vasto S, Candore G, Listi F, et al. Inflammation, genes and zinc in Alzheimer's disease. Brain Res Rev 2008;58:96-105
66. Gilroy DW, Lawrence T, Perreti M, et al. new opportunities for drug discovery. Nat Rev Drug Discovery 2004;3:401-16
67. Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol 2009;9:833-44
68. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9 (Pubitemid 17052899)
69. Crotzer VL, Blum JS. Cytosol to lysosome transport of intracellular antigens during immune surveillance. Traffic 2010;9:10-6 (Pubitemid 350263459)
70. Linkermann A, Qian J, Lettau M, et al. Considering Fas ligands as a target for therapy. Expert Opin Ther Targets 2005;9:119-34 (Pubitemid 40347230)
71. Zitvogel L, Apetoh L, Chiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008;8:59-73
72. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statin. Circ Res 2010;107:1170-84
73. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J Immunol 2011;186:1325-31
74. Florescu A, Amir E, Bouganim N, Clemons M. Immune therapy for breast cancer in 2010-hype or hope? Curr Oncol 2011;18:e9-18
75. Rove KO, Flaig TW. A renaissance in the medical treatment of advanced prostate cancer. Oncology 2010;24:1308-18
76. Coss CC, Bohl CE, Dalton JT. Cancer cachexia therapy:a key weapon in the fight against cancer. Curr Opin Clin Nutr Metab Care 2011;14:268-73